March 27, 2024
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today… Read More
learn more
March 11, 2024
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced a late… Read More
learn more
